Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

EMA Starts Review of Tredaptive, Pelzont, Trevaclyn Medicines

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/21/2012 | 11:46am CEST

LONDON--The European Medicines Agency, or EMA, Friday said it has started a review of the safety and efficacy of Tredaptive, Pelzont and Trevaclyn, identical medicines that are used to treat adults with dyslipidaemia, particularly combined mixed dyslipidaemia and primary hypercholesterolaemia.

MAIN FACTS:

-Review was triggered because the Agency was informed by the pharmaceutical company Merck, Sharp & Dohme of the preliminary results of a large, long-term study comparing the clinical effects of adding these medicines to statins (standard medicines used to reduce cholesterol) with statin treatment alone.

-Study raises questions about the efficacy of the medicine when added to statins, as this did not reduce the risk of major vascular events compared with statin therapy alone.

-Preliminary results saw a higher frequency of non-fatal but serious side effects in patients taking the medicines than in patients only taking statins.

-Pharmacovigilance Risk Assessment Committee (>> PRODUCTIVITY TECHS CORP) will assess the data and make a recommendation to the Committee on Medicinal Products for Human Use (>> Champion Industries, Inc.), which will issue an opinion on the regulatory action required.

-Opinion is expected in January 2013.

-Write to Tapan Panchal at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : PRODUCTIVITY TECHS CORP, Champion Industries, Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK AND COMPANY
10/16 ASTRAZENECA : Pharma and medtech industries prepare for hard Brexit
10/16 MERCK AND : Makes $3 Million Charitable Donation to Support Swim Across America
10/16 MERCK AND : Joins with the American Liver Foundation to Educate U.S. Veterans on..
10/16 BERGENBIO : BGB324, BerGenBio's Selective First-in-Class AXL Inhibitor, Featured..
10/16 BERGENBIO : BGB324, BerGenBio's Selective First-in-Class AXL Inhibitor, Featured..
10/13 MERCK AND : Salk Researchers Awarded $2.5 Million for Innovative Pancreatic Canc..
10/13 MERCK AND : Provides Update on Anacetrapib Development Program
10/12 MERCK : Makes $3 Million Charitable Donation to Support Swim Across America
10/12 MERCK : Joins with the American Liver Foundation to Educate U.S. Veterans on Chr..
10/12 MERCK AND : Bedell Frazier Investment Counseling Has Increased Its Position in W..
More news
News from SeekingAlpha
10/17 Dynavax Reports More Good News
10/16 Merck's Risk/Reward Is Compelling
10/16 Merck Pulls The Plug On Cholesterol Drug
10/16 President Trump at it again with comments on "out of control" drug prices
10/16 SANOFI : Upward Trajectory In 2017
Financials ($)
Sales 2017 40 272 M
EBIT 2017 13 680 M
Net income 2017 5 795 M
Debt 2017 8 102 M
Yield 2017 2,98%
P/E ratio 2017 31,60
P/E ratio 2018 18,84
EV / Sales 2017 4,49x
EV / Sales 2018 4,42x
Capitalization 173 B
Chart MERCK AND COMPANY
Duration : Period :
Merck and Company Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 69,6 $
Spread / Average Target 9,9%
EPS Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Clark Golestani Chief Information Officer & Executive VP
Thomas Henry Glocer Independent Director
Rochelle B. Lazarus Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK AND COMPANY7.68%172 751
JOHNSON & JOHNSON18.42%365 346
NOVARTIS13.23%226 956
ROCHE HOLDING LTD.5.20%215 359
PFIZER11.88%214 265
AMGEN25.17%132 728